Alkermes plc reported second quarter 2026 total revenues of $496.0 million, a 27% increase from the prior year period, driven by strong proprietary product sales. GAAP net income was $0.5 million, while Adjusted EBITDA reached $139.2 million. The company announced that Blair Jackson will assume the role of Chief Executive Officer on August 1, 2026, succeeding Chairman Richard Pops, who will remain on the Board. Financial expectations for the full year 2026 were updated, with the GAAP net loss guidance widened to ($95)–($115) million from the previous ($70)–($90) million range, primarily due to a $26.4 million increase in the fair value of contingent consideration related to the Avadel acquisition. Alkermes operates in the biopharmaceutical industry, developing and commercializing innovative medicines in neuroscience.

Alkermes plc and Amneal Pharmaceuticals LLC terminated their Authorized Generic Product Supply Agreement dated September 9, 2025, regarding the distribution of an authorized generic version of VIVITROL in the United States. Amneal notified the Company after a failure to meet certain terms, which the Company did not incur any penalties for. Alkermes plc is a biopharmaceutical company focused on the development and commercialization of central nervous system and CNS-related products.

On June 15, 2026, Alkermes plc announced that the U.S. Food and Drug Administration granted orphan drug designation to alixorexton for treating idiopathic hypersomnia. Additionally, the European Commission granted orphan drug designation to alixorexton for the treatment of narcolepsy. Alkermes plc is a biopharmaceutical company focused on developing medical treatments.